Biogen logo — Innovative therapies worldwide for people living with seriou...

Biogen

Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases

Founded 1978 United States Cambridge, United States 7823 employees IPO Total: $4.57M Biotechnology, Health Care +1

General Information

Company Name Biogen
Founded Year 1978
Location United States Cambridge, United States +3
Employees 7823
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage IPO
Social

Get notified when Biogen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 01, 2026

Biogen is collaborating with Stoke Therapeutics to share their latest findings in Dravet syndrome at #EEC2026.

Event Participation Aug 13, 2026

Biogen participated in the rideATAXIA Boston event to raise awareness and support research for Friedreich ataxia.

AI Insight

Bounce Watch AI
2 months ago

Biogen is demonstrating robust strategic momentum, highlighted by the recent acquisition of Apellis Pharmaceuticals and significant R&D progress, including positive Phase 3 results for an investigational SLE treatment and Breakthrough Therapy Designation for an SMA therapy. These advancements are further supported by the commissioning of a new manufacturing facility in Solothurn, indicating a concerted effort towards pipeline commercialization and scaling global operations.

Signal Types
Acquisition Regulatory Approval Clinical Progress Manufacturing Expansion Partnership
Strategic Labels
Portfolio Expansion R&D Acceleration Operational Scaling
Next Move: Commercialization
·
Impact: 9/10
·
Ideal For: Large-Cap Biotech Investors — Post-IPO

About Biogen

Biogen, founded in 1978, is a pioneering force in the biotechnology sector, with a particular focus on developing innovative therapies for serious neurological and neurodegenerative diseases. As indicated by their slogan, "Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases," Biogen seeks to transform patients' lives while delivering value for shareholders.

Headquartered in the United States, with around 7,000 employees globally, Biogen operates through an extensive international network, including research operations in Cambridge, Massachusetts, and international headquarters in Baar, Switzerland. The company’s approach combines a deep understanding of human biology with cutting-edge technology to advance first-in-class treatments.

Despite a period since their last investment—$2.07M grant in April 2018—Biogen stands out as an established leader in the Health Care industry, offering a robust platform for investors seeking long-term growth in the dynamic Health and Wellness landscape.

Taxonomy: Neurological Disorders, Neurodegenerative Diseases, Innovative Therapies, Multiple Sclerosis, Biological Products, Research and Development, Global Distribution, Manufacturing Facilities, First-in-Class Treatments, Cutting-edge Science, Patient-focused

Services & Products

Drug Development
Research and Development
Clinical Trials
Medicines Marketing
Corporate Responsibility Initiatives

Target Customers

Patients with Neurological Conditions Patients with Immunological Conditions Patients with Rare Diseases Healthcare Professionals Medical Researchers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• - 01 Apr 2018
IPO •••••• - 01 Sep 1991
Growth Equity Non Vc •••••• 1
Investor
01 Jan 1986

Biogen Alternatives & Competitors

View All Alternatives
Biogen vs

Amarin Corporation plc is a biopharmaceutical company focused on therapeutics to improve cardiovascu...

Post Ipo Equity
442 employees
Biopharma, Biotechnology
Biogen vs
MPC Therapeutics
MPC Therapeutics Switzerland

Biotech company focused on cellular rejuvenation to fight cancer & degenerative pathologies.

Debt Financing
6 employees
Biotechnology, Health Care
Biogen vs
MCI
MCI Switzerland

The power of people united in purpose is unstoppable. MCI is a global engagement and marketing agen...

2635 employees
Marketing

FAQ About Biogen

Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases
Biogen was founded in 1978.
Biogen is headquartered in Cambridge, United States.
Biogen operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Biogen has approximately 7823 employees.
Biogen has completed 3 funding rounds, raising a total of $4.57M. The latest funding stage is IPO.
Biogen offers: Drug Development, Research and Development, Clinical Trials, Medicines Marketing, Corporate Responsibility Initiatives.
Top alternatives and competitors to Biogen include Amarin Corporation, MPC Therapeutics, MCI, Bioverativ, a Sanofi company, Diamond Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biogen and Amarin Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Biogen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy